TY  - JOUR
AU  - Lindemann, K
AU  - Kristensen, G
AU  - Mirza, M R
AU  - Davies, L
AU  - Hilpert, F
AU  - Romero, I
AU  - Ayhan, A
AU  - Burges, A
AU  - Rubio, M J
AU  - Raspagliesi, F
AU  - Huizing, M
AU  - Creemers, G-J
AU  - Lykka, M
AU  - Lee, C K
AU  - Gebski, V
AU  - Pujade-Lauraine, E
PY  - 2016
DO  - 10.1093/annonc/mdw238
UR  - http://hdl.handle.net/10668/10262
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from patients with platinum-sensitive disease receiving chemotherapy alone. We assessed concordance between CA-125-defined and RECIST-defined PD using data...
LA  - en
KW  - CA-125
KW  - RECIST
KW  - ovarian cancer
KW  - platinum resistance
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bevacizumab
KW  - CA-125 Antigen
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Doxorubicin
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Ovarian Neoplasms
KW  - Platinum
KW  - Prognosis
KW  - Response Evaluation Criteria in Solid Tumors
TI  - Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
TY  - research article
VL  - 27
ER  -